NVDA vs LLY
NVIDIA Corporation vs Eli Lilly and Company · Updated Sep 11, 2026
NVDA — 11 winsLLY — 12 wins
Price Performance
NVDA +23.94%LLY +47.84%
Performance
| NVDA | LLY | |
|---|---|---|
| 1 Month | +0.46% | -7.33% |
| 3 Months | +9.02% | -0.92% |
| 6 Months | +17.45% | +12.61% |
| YTD | +17.16% | +4.77% |
| 1 Year | +27.96% | +50.00% |
| 3 Year | +389.21% | +193.71% |
| 5 Year | +1576.89% | +585.20% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVDA | +16.3% | +34.8% | +178.8% | +245.9% | -51.5% | +124.3% | +117.7% | +72.4% | -32.9% | +89.8% | +229.9% | +63.7% |
| LLY | +3.5% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
Valuation
| NVDA | LLY | |
|---|---|---|
| P/E Ratio | 44.59 | 40.00 |
| Forward P/E | 12.56 | 24.06 |
| PEG Ratio | 1.20 | 1.77 |
| P/S Ratio | 25.84 | 14.65 |
| P/B Ratio | 35.47 | 33.93 |
| EV/EBITDA | 38.60 | 32.78 |
Financials
| NVDA | LLY | |
|---|---|---|
| EPS (TTM) | $4.90 | $28.15 |
| Gross Margin | +75.00% | +78.98% |
| Operating Margin | +65.02% | +46.44% |
| Net Margin | +63.06% | +37.36% |
| ROE | +76.33% | +81.01% |
| ROA | +58.06% | +21.68% |
| Debt/Equity | 0.07 | 1.39 |
Growth
| NVDA | LLY | |
|---|---|---|
| Revenue Growth YoY | +73.21% | +55.55% |
| Revenue Growth QoQ | +19.51% | +2.63% |
| EPS Growth YoY | +97.75% | +169.94% |
| EPS Growth QoQ | +35.38% | +11.77% |
Technical
| NVDA | LLY | |
|---|---|---|
| RSI (14) | 54.48 | 39.14 |
| % From 20-Day SMA | -0.91% | -5.21% |
| % From 50-Day SMA | +2.98% | -5.08% |
| % From 200-Day SMA | +10.76% | +5.77% |
| % From 52-Week High | -7.63% | -12.90% |
| % From 52-Week Low | +33.01% | +58.12% |
Analyst Ratings
NVDA
Buy(71 analysts)
Strong SellHoldStrong Buy
Price Target
$345.21
+50.11% upside
LLY
Buy(25 analysts)
Strong SellHoldStrong Buy
Price Target
$1341.63
+17.33% upside
Overview
| NVDA | LLY | |
|---|---|---|
| Sector | Technology | Healthcare |
| Industry | Semiconductors | Drug Manufacturers - General |
| Exchange | NASDAQ | NYSE |
| Market Cap | $5.58T | $1.06T |
| Shares Outstanding | 24.22B | 941.7M |
| Avg Volume (10D) | 146.34M | 2.44M |
| Dividend Yield | 0.12% | 0.60% |
Frequently Asked Questions
Is NVDA or LLY a better buy right now?
Based on 23 comparable metrics, LLY leads in 12 categories while NVDA leads in 11. LLY has a consensus analyst rating with 25 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, NVDA or LLY?
Over the past year, NVDA returned +27.96% compared to LLY's +50.00%. In the short term (1 month), NVDA returned +0.46% vs LLY's -7.33%.
Is NVDA or LLY more expensive?
NVDA trades at a P/E of 44.59 compared to LLY's 40.00. On a price-to-sales basis, NVDA trades at 25.84x vs LLY's 14.65x. Forward P/E: NVDA at 12.56 vs LLY at 24.06.
Which stock has higher growth, NVDA or LLY?
NVDA's revenue grew +73.21% year-over-year compared to LLY's +55.55%. EPS growth: NVDA at +97.75% vs LLY at +169.94%.
Do NVDA and LLY pay dividends?
NVDA pays a dividend with a yield of 0.12%. LLY pays a dividend with a yield of 0.60%.
Which stock do analysts prefer, NVDA or LLY?
NVDA has 71 analysts with a target price of $345.21 (+50.11% upside). LLY has 25 analysts with a target of $1341.63 (+17.33% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.